|
Balance Sheet Cash Flow Statement 616 N. North Ct. Palatine, IL 60067 IL Tel. 847-705-7709 Fax 847-705-5399 |
Type: Public
On the web:
http://acurapharm.com
Employees:
15
Employee growth: 7.1%
Acura Pharmaceuticals is working to make it harder to abuse otherwise good drugs. The company has developed a technology to add abuse-deterring agents to commonly abused pharmaceuticals. If a drug with these agents (what Acura calls Aversion Technology) is taken in excess, the ingredients cause unpleasant symptoms shortly after ingestion. If a tablet is crushed and inhaled other ingredients will cause nasal irritation; and if an abuser attempts to dissolve the powder, it will form a non-injectable gel. Lead product candidate Acurox combines Aversion Technology with the commonly abused opioid painkiller oxycodone HCl.
Key numbers for fiscal year ending December, 2008:
Sales: $44.4M
One year growth: 593.9%
Net income: $14.5M
Officers:
Chairman: Richard J. Markham
President, CEO, and Director: Andrew D. (Andy) Reddick
SVP and COO: Robert B. Jones
Competitors:
Elite Pharmaceuticals
Endo Pharmaceuticals
Pain Therapeutics
